REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio operating margin
Operating margin is operating income as a percentage of revenue.
Regenxbio's operating margin for the twelve months ending Jun 30, 2026 was -94.1%. For fiscal 2025 it was -94.6%, against -280.0% the year before. The highest annual figure on record is 40.3% in fiscal 2018.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -94.6% | +185.5 |
| FY2024 | Dec 31, 2024 | -280.0% | +17.1 |
| FY2023 | Dec 31, 2023 | -297.1% | −63.9 |
| FY2022 | Dec 31, 2022 | -233.2% | −267.2 |
| FY2021 | Dec 31, 2021 | 34.0% | +111.2 |
| FY2020 | Dec 31, 2020 | -77.1% | +345.8 |
| FY2019 | Dec 31, 2019 | -422.9% | −463.2 |
| FY2018 | Dec 31, 2018 | 40.3% | +770.5 |
| FY2017 | Dec 31, 2017 | -730.2% | +693.7 |
| FY2016 | Dec 31, 2016 | -1423.8% | −1118.9 |
| FY2015 | Dec 31, 2015 | -304.9% | −244.8 |
| FY2014 | Dec 31, 2014 | -60.2% | +18.3 |
| FY2013 | Dec 31, 2013 | -78.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 27.1% | +323.3 |
| Q1 FY2026 | Mar 31, 2026 | -1304.0% | −1317.6 |
| Q4 FY2025 | Dec 31, 2025 | -190.0% | +52.2 |
| Q3 FY2025 | Sep 30, 2025 | -176.3% | +80.3 |
| Q2 FY2025 | Jun 30, 2025 | -296.3% | −44.9 |
| Q1 FY2025 | Mar 31, 2025 | 13.6% | +422.4 |
| Q4 FY2024 | Dec 31, 2024 | -242.1% | +45.5 |
| Q3 FY2024 | Sep 30, 2024 | -256.6% | −31.9 |
| Q2 FY2024 | Jun 30, 2024 | -251.3% | +114.6 |
| Q1 FY2024 | Mar 31, 2024 | -408.8% | −63.1 |
| Q4 FY2023 | Dec 31, 2023 | -287.7% | −103.4 |
| Q3 FY2023 | Sep 30, 2023 | -224.7% | +43.3 |
| Q2 FY2023 | Jun 30, 2023 | -366.0% | −174.4 |
| Q1 FY2023 | Mar 31, 2023 | -345.7% | −23.8 |
| Q4 FY2022 | Dec 31, 2022 | -184.3% | −263.0 |
| Q3 FY2022 | Sep 30, 2022 | -268.0% | −81.6 |
| Q2 FY2022 | Jun 30, 2022 | -191.5% | +45.5 |
| Q1 FY2022 | Mar 31, 2022 | -321.9% | −88.7 |
| Q4 FY2021 | Dec 31, 2021 | 78.7% | +328.8 |
| Q3 FY2021 | Sep 30, 2021 | -186.4% | −200.5 |
| Q2 FY2021 | Jun 30, 2021 | -237.0% | +15.5 |
| Q1 FY2021 | Mar 31, 2021 | -233.2% | −19.6 |
| Q4 FY2020 | Dec 31, 2020 | -250.2% | +92.5 |
| Q3 FY2020 | Sep 30, 2020 | 14.1% | +258.3 |
| Q2 FY2020 | Jun 30, 2020 | -252.5% | +215.3 |
| Q1 FY2020 | Mar 31, 2020 | -213.7% | +3848.1 |
| Q4 FY2019 | Dec 31, 2019 | -342.7% | −348.7 |
| Q3 FY2019 | Sep 30, 2019 | -244.2% | +184.1 |
| Q2 FY2019 | Jun 30, 2019 | -467.9% | −483.7 |
| Q1 FY2019 | Mar 31, 2019 | -4061.8% | −4138.8 |
| Q4 FY2018 | Dec 31, 2018 | 6.0% | +819.6 |
| Q3 FY2018 | Sep 30, 2018 | -428.3% | +1166.7 |
| Q2 FY2018 | Jun 30, 2018 | 15.9% | +245.3 |
| Q1 FY2018 | Mar 31, 2018 | 77.1% | +5114.9 |
| Q4 FY2017 | Dec 31, 2017 | -813.6% | +393.3 |
| Q3 FY2017 | Sep 30, 2017 | -1595.0% | +13339.4 |
| Q2 FY2017 | Jun 30, 2017 | -229.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -5037.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -1206.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -14934.4% | – |
See a number that looks wrong?